A carregar...
Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri®) in Inflammatory Diseases
Natalizumab (Tysabri®) was the first adhesion molecule antagonist to make it into clinical trial for patients with multiple sclerosis (MS) and other inflammatory disorders. Natalizumab is a humanized recombinant monoclonal antibody (MAb) that binds to the alpha (α)(4) chain of the α(4) beta (β)(1) (...
Na minha lista:
| Publicado no: | CNS Drug Rev |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Publishing Inc
2007
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6494150/ https://ncbi.nlm.nih.gov/pubmed/17461891 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1527-3458.2007.00003.x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|